Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer

Phase 1

Completed

Conditions: Stage IIIC Breast Cancer
Stage IIIB Breast Cancer
Stage IIIA Breast Cancer
Breast Cancer
Male Breast Cancer
Stage II Breast Cancer

Interventions: Drug: tipifarnib
Drug: paclitaxel
Drug: doxorubicin
Drug: cyclophosphamide

First Posted Date: 2007-05-07

Last Posted Date: 2021-02-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 60

Registration Number: NCT00470301

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

and more 4 locations

Phase Ⅱ Clinical Study of R435 (Bevacizumab) in Combination With Paclitaxel in Patients With Inoperable Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: bevacizumab
Drug: Paclitaxel

First Posted Date: 2007-04-27

Last Posted Date: 2012-04-26

Lead Sponsor: Chugai Pharmaceutical

Target Recruit Count: 122

Registration Number: NCT00467012

Locations: 🇯🇵
Kyushu region, Kyushu, Japan
🇯🇵
Kanto Region, Kanto, Japan
🇯🇵
Kinki Region, Kinki, Japan

and more 2 locations

Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors

Phase 2

Completed

Conditions: Childhood Extracranial Germ Cell Tumor
Childhood Malignant Ovarian Germ Cell Tumor
Childhood Malignant Testicular Germ Cell Tumor
Ovarian Yolk Sac Tumor
Recurrent Childhood Malignant Germ Cell Tumor
Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
Ovarian Embryonal Carcinoma
Recurrent Malignant Testicular Germ Cell Tumor
Ovarian Choriocarcinoma
Recurrent Ovarian Germ Cell Tumor

Interventions: Drug: Carboplatin
Biological: Filgrastim
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel

First Posted Date: 2007-04-27

Last Posted Date: 2018-08-29

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 20

Registration Number: NCT00467051

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Palmetto Health Richland, Columbia, South Carolina, United States

and more 92 locations

Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer

Phase 2

Conditions: Cervical Cancer

First Posted Date: 2007-04-19

Last Posted Date: 2013-08-26

Lead Sponsor: University College London Hospitals

Target Recruit Count: 50

Registration Number: NCT00462397

Locations: 🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom
🇬🇧
Royal Marsden - London, London, England, United Kingdom
🇬🇧
University College of London Hospitals, London, England, United Kingdom

MONET1-MOtesanib NSCLC Efficacy and Tolerability Study

Phase 3

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: placebo
Drug: AMG 706
Drug: paclitaxel
Drug: carboplatin

First Posted Date: 2007-04-13

Last Posted Date: 2015-09-07

Lead Sponsor: Amgen

Target Recruit Count: 1450

Registration Number: NCT00460317

Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Drug: Zactima
Procedure: neoadjuvant therapy

First Posted Date: 2007-04-11

Last Posted Date: 2019-03-26

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 2

Registration Number: NCT00459121

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor

Phase 2

Withdrawn

Conditions: Unknown Primary Tumors

First Posted Date: 2007-04-10

Last Posted Date: 2015-05-08

Lead Sponsor: Rigshospitalet, Denmark

Registration Number: NCT00458315

Locations: 🇩🇰
Rigshospitalet, Dept of Oncology, Copenhagen, Denmark

Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Ixabepilone
Drug: Paclitaxel
Drug: Cyclophosphamide
Drug: Doxorubicin

First Posted Date: 2007-04-03

Last Posted Date: 2016-02-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 384

Registration Number: NCT00455533

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Florida Cancer Research Institute, Davie, Florida, United States
🇺🇸
Albert Einstein Cancer Center, Bronx, New York, United States

and more 8 locations